NASDAQ:ALDX Aldeyra Therapeutics Q1 2024 Earnings Report $2.76 +0.10 (+3.76%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$2.80 +0.05 (+1.63%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Aldeyra Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.08Beat/MissMissed by -$0.06One Year Ago EPSN/AAldeyra Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAldeyra Therapeutics Announcement DetailsQuarterQ1 2024Date5/2/2024TimeN/AConference Call DateThursday, May 2, 2024Conference Call Time4:00PM ETUpcoming EarningsAldeyra Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 1, 2025Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aldeyra Therapeutics Earnings HeadlinesBragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the FirmApril 28 at 9:00 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 28 at 6:06 PM | prnewswire.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 29, 2025 | Brownstone Research (Ad)ALDX SHAREHOLDER REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about Securities InvestigationApril 28 at 9:06 AM | markets.businessinsider.comALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA LawApril 27 at 8:20 AM | globenewswire.comALDX SHAREHOLDER ALERT: BFA Law Reminds Aldeyra Therapeutics, Inc. Investors of the Continuing Securities InvestigationApril 26 at 9:41 AM | markets.businessinsider.comSee More Aldeyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email. Email Address About Aldeyra TherapeuticsAldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.View Aldeyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Upcoming Earnings QUALCOMM (4/30/2025)Automatic Data Processing (4/30/2025)Microsoft (4/30/2025)Meta Platforms (4/30/2025)KLA (4/30/2025)Equinix (4/30/2025)Lloyds Banking Group (4/30/2025)Itaú Unibanco (4/30/2025)Banco Santander (4/30/2025)Equinor ASA (4/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
